TY - JOUR
T1 - Effects of transdermal testosterone on natriuretic peptide levels in women
T2 - A randomized placebo-controlled pilot study
AU - Lin, Eleanor
AU - McCabe, Elizabeth
AU - Newton-Cheh, Christopher
AU - Bloch, Kenneth
AU - Buys, Emmanuel
AU - Wang, Thomas
AU - Miller, Karen K.
N1 - Funding Information:
Supported by Food and Drug Administration grant FD-R-001981 and National Institutes of Health grants M01-RR-01066 and T32-DK-007028-36 . Procter and Gamble Pharmaceuticals provided study medication and placebo only.
PY - 2012/2
Y1 - 2012/2
N2 - Objective: To investigate whether testosterone administration alters natriuretic peptide levels in women. Design: Three-month, double-blind, randomized, placebo-controlled study. Setting: Clinical research center. Patient(s): Fifty-one women with hypoandrogenemia due to hypopituitarism. Intervention(s): Transdermal testosterone (300 μg daily) or placebo patch. Main Outcome Measure(s): N-Terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Result(s): NT-proBNP levels decreased in the transdermal testosterone group compared with placebo over three months. The difference between groups remained significant after controlling for baseline age, systolic blood pressure, body mass index, and homeostasis model assessment of insulin resistance. Change in NT-proBNP over 3 months was inversely associated with change in free testosterone levels. Conclusion(s): Testosterone administration to women results in decreased natriuretic peptide levels, suggesting that testosterone may be an inverse regulator of the natriuretic peptide system. Clinical Trials Registration Number: NCT00027430.
AB - Objective: To investigate whether testosterone administration alters natriuretic peptide levels in women. Design: Three-month, double-blind, randomized, placebo-controlled study. Setting: Clinical research center. Patient(s): Fifty-one women with hypoandrogenemia due to hypopituitarism. Intervention(s): Transdermal testosterone (300 μg daily) or placebo patch. Main Outcome Measure(s): N-Terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Result(s): NT-proBNP levels decreased in the transdermal testosterone group compared with placebo over three months. The difference between groups remained significant after controlling for baseline age, systolic blood pressure, body mass index, and homeostasis model assessment of insulin resistance. Change in NT-proBNP over 3 months was inversely associated with change in free testosterone levels. Conclusion(s): Testosterone administration to women results in decreased natriuretic peptide levels, suggesting that testosterone may be an inverse regulator of the natriuretic peptide system. Clinical Trials Registration Number: NCT00027430.
KW - Testosterone
KW - natriuretic peptides
UR - http://www.scopus.com/inward/record.url?scp=84856394319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856394319&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2011.11.001
DO - 10.1016/j.fertnstert.2011.11.001
M3 - Article
C2 - 22137497
AN - SCOPUS:84856394319
SN - 0015-0282
VL - 97
SP - 489
EP - 493
JO - Fertility and sterility
JF - Fertility and sterility
IS - 2
ER -